openPR Logo
Press release

Investigation announced for Long-Term Investors in shares of Kadmon Holdings Inc (NYSE: KDMN)

06-26-2021 02:51 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of current long term investors in Kadmon Holdings Inc (NYSE: KDMN) shares.

An investigation on behalf of current long term investors in Kadmon Holdings Inc (NYSE: KDMN) shares.

An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Kadmon Holdings Inc.

Investors who are current long term investors in Kadmon Holdings Inc (NYSE: KDMN) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NYSE: KDMN stocks follows a lawsuit filed against Kadmon Holdings Inc over alleged securities laws violations. The investigation on behalf of current long term investors in NYSE: KDMN stocks, concerns whether certain Kadmon Holdings Inc directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the Eastern District of New York the plaintiff alleges that the Defendants made false and/or misleading statements and/or failed to disclose that the Belumosudil NDA was incomplete and/or deficient, that the additional new data that the Company submitted in support of the Belumosudil NDA in response to an information request from the FDA materially altered the NDA submission, that accordingly, the initial Belumosudil NDA submission lacked the degree of support that the Company had led investors to believe, that accordingly, the FDA was likely to extend the PDUFA target action date to review the Belumosudil NDA, and that as a result, the Company's public statements were materially false and misleading at all relevant times.

Those who purchased shares of Kadmon Holdings Inc (NYSE: KDMN) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Long-Term Investors in shares of Kadmon Holdings Inc (NYSE: KDMN) here

News-ID: 2314469 • Views:

More Releases from Shareholders Foundation

Investigation announced for Long-Term Investors in shares of West Pharmaceutical Services, Inc. (NYSE: WST) over potential Wrongdoing
Investigation announced for Long-Term Investors in shares of West Pharmaceutical …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of West Pharmaceutical Services, Inc.. Investors who are current long term investors in West Pharmaceutical Services, Inc. (NYSE: WST) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in (NYSE: WST stocks follows a lawsuit filed
Investigation announced for Long-Term Investors in Open Lending Corporation (NASDAQ: LPRO) over potential Wrongdoing
Investigation announced for Long-Term Investors in Open Lending Corporation (NAS …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Open Lending Corporation. Investors who are current long term investors in Open Lending Corporation (NASDAQ: LPRO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: LPRO stocks follows a lawsuit filed against Open
Investigation announced for Long-Term Investors in shares in BigBear.ai Holdings, Inc. (NYSE: BBAI)
Investigation announced for Long-Term Investors in shares in BigBear.ai Holdings …
An investigation on behalf of current long-term investors in shares of BigBear.ai Holdings, Inc. (NYSE: BBAI) concerning potential breaches of fiduciary duties by certain directors and officers of BigBear.ai Holdings, Inc. was announced. Investors who are current long term investors in BigBear.ai Holdings, Inc. (NYSE: BBAI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm
Lawsuit filed for Investors who lost money with shares of DoubleVerify Holdings, Inc. (NYSE: DV)
Lawsuit filed for Investors who lost money with shares of DoubleVerify Holdings, …
An investor, who purchased shares of DoubleVerify Holdings, Inc. (NYSE: DV), filed a lawsuit over alleged violations of Federal Securities Laws by DoubleVerify Holdings, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of DoubleVerify Holdings, Inc. (NYSE: DV) have certain options and for certain investors are short and strict deadlines running. Deadline: July 21, 2025. NYSE: DV investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com

All 5 Releases


More Releases for Kadmon

Diffuse Cutaneous Systemic Sclerosis Clinical Trials | A Drug Pipeline Analysis …
DelveInsight's 'Diffuse Cutaneous Systemic Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and pipeline Diffuse Cutaneous Systemic Sclerosis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Diffuse Cutaneous Systemic Sclerosis pipeline domain. Download sample pages: https://www.delveinsight.com/report-store/diffuse-cutaneous-systemic-sclerosis-dcssc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr Key Takeaways from the Diffuse Cutaneous Systemic Sclerosis Pipeline Report Over 15+ Diffuse Cutaneous Systemic Sclerosis pipeline therapies
Diffuse Cutaneous Systemic Sclerosis Clinical Trials | A Drug Pipeline Analysis …
DelveInsight's 'Diffuse Cutaneous Systemic Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and pipeline Diffuse Cutaneous Systemic Sclerosis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Diffuse Cutaneous Systemic Sclerosis pipeline domain. Download sample pages: https://www.delveinsight.com/report-store/diffuse-cutaneous-systemic-sclerosis-dcssc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr Key Takeaways from the Diffuse Cutaneous Systemic Sclerosis Pipeline Report Over 15+ Diffuse Cutaneous Systemic Sclerosis pipeline therapies
Wilson's Disease Treatment Market Projected to Show Strong Growth| Noble Pharma, …
Advance Market Analytics published a new research publication on "Wilson's Disease Treatment Market Insights, to 2028" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Wilson's Disease Treatment market was mainly driven by the increasing R&D spending across the world. Get Free Exclusive PDF Sample
Deadline on June 2nd coming up in Lawsuit for Investors in Kadmon Holdings Inc ( …
The Shareholders Foundation announced that a deadline is coming up on June 2, 2021 in the lawsuit filed for certain investors of Kadmon Holdings Inc (NYSE: KDMN) over alleged securities laws violations by Kadmon Holdings Inc. Investors who purchased shares of Kadmon Holdings Inc (NYSE: KDMN) have certain options and there are strict and short deadlines running. Deadline: June 2, 2021. NYSE: KDMN stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com
Lawsuit filed for Investors in shares of Kadmon Holdings Inc (NYSE: KDMN)
An investor, who purchased shares of Kadmon Holdings Inc (NYSE: KDMN), filed a lawsuit over alleged violations of Federal Securities Laws by Kadmon Holdings Inc. Investors who purchased shares of Kadmon Holdings Inc (NYSE: KDMN) have certain options and for certain investors are short and strict deadlines running. Deadline: June 2, 2021. NYSE: KDMN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. New York based Kadmon
Rho Kinase Inhibitor Therapeutics- Pipeline Analysis 2018 | BioAxone BioSciences …
Rho kinase inhibitor, also known as ROCK inhibitor, inhibits the rho kinases, a family of small GTP-binding protein. Rho kinases are found to regulate cell motility, proliferation, shape, gene expression, apoptosis, and are also involved in the signalling pathway. Download the sample report @ https://www.pharmaproff.com/request-sample/1196 The inhibition of rho kinases has shown some beneficial effects in cardiovascular diseases, including systemic hypertension, vasospastic angina, stable effort stigma, pulmonary hypertension, stroke, and heart